Listing 1 - 10 of 10 |
Sort by
|
Choose an application
Choose an application
Liver --- Liver Diseases. --- Gastroenterology. --- Diseases
Choose an application
Liver Diseases --- Biliary Tract Diseases --- Child --- Infant
Choose an application
A volume in the popular Pattern Recognition Series, Practical Hepatic Pathology: A Diagnostic Approach features completely updated and reorganized content, resulting in a truly practical guide to understanding liver pathology. Dr. Romil Saxena presents interpretation of liver biopsies according to a pattern-based approach that begins with recognition of the predominant histological pattern of injury, followed by identification of secondary features and appropriate work-up that lead you away from pitfalls to the best diagnosis.
Liver --- Liver --- Liver Diseases --- Liver Diseases --- Liver --- Pathophysiology. --- Diseases --- Diagnosis. --- pathology. --- diagnosis. --- pathology.
Choose an application
Gastroenterology --- Gastrointestinal Diseases --- Liver Diseases --- Internship and Residency
Choose an application
Il semble indéniable que la NASH soit devenue un sujet de préoccupation de santé publique pour lequel la mise en place de solutions spécifiques se trouve être nécessaire au vue des épidémies actuelles d'obésité et de diabète de type II qui s'observent dans les pays développés. La NASH complication hépatique de l'obésité et du syndrome métabolique est une pathologie hépatique qui se caractérise par l'accumulation de graisses sous forme de triglycérides dans les hépatocytes, s'y associe une inflammation, des lésions hépatocellulaires avec ou sans fibrose pouvant évoluer en cirrhose et en hépato carcinome. De plus, la NASH augmente les risques de maladies cardiovasculaires. Au vu de la gravité des diverses complications, un grand besoin de traitements existe puisque actuellement aucun traitement n'a été validé pour cette indication. Genfit a élaboré pour ce faire un candidat médicament, Elafibranor. C'est un double agoniste des PPARs qui possède une activité préférentielle pour PPAR-a et une activité supplémentaire pour PPAR-/ô. Les PPARs ont plusieurs effets métaboliques favorables tels que l'amélioration de la -oxydation des acides gras, du catabolisme des lipides, de la sensibilité à l'insuline et bien d'autres, tout en atténuant l'inflammation hépatique ce qui en font des cibles d'intérêt dans le traitement de la NASH. Actuellement, Elafibranor est rentrée en étude de phase III, au vu des différents résultats prometteurs obtenus lors des phases' précliniques et cliniques. Elafibranor a démontré divers effets bénéfiques prometteurs tels que l'amélioration de l'inflammation, de la stéatose et de la fibrose pour les traitements de la NASH tout en ayant un profil de sécurité satisfaisant. Des questions restent cependant en suspens et nous attendons avec impatience les résultats de la phase III pour déterminer l'avenir d'Elafibranor dans le traitement de la stéatose hépatique non alcoolique. Non-alcoholic fatty liver disease (NAFLD) is a hepatic complication of obesity and metabolic syndrome that affect a wide ride of individuals. As well as, it increases the risk of cardio-vascular diseases. It’ characterized by the accumulation of fat the form of triglycerides in the hepatocytes and is considered to be the most common cause of liver dysfunction in the western countries. It could progress to a more severe disease of hepatic inflammation leading to the development of a non-alcoholic steato-hepatitis (NASH), with or without fibrosis; as well as the development of liver fibrosis and hepatocarcinoma. The diagnosis is based on the histological findings of steatosis and inflammation of the hepatocytes, leading to their damage. Currently there is not approved therapy for NASH; and trials are being held to find the appropriate treatment and thus help decrease the burden of the disease. Genfit has developed a drug called Elafibranor. It is dual PPAR-α/δ agonist. PPARs are lipid-activated nuclear receptors. Activation of different PPARs represents an important pharmacological target because of multiple metabolic effects on carbohydrate and lipid metabolism, as well as on inflammatory response. This is a promising drug for the treatment of NASH seeing the promising results of the preclinical and clinical phases. Initial results have showed the beneficial effect of Elafibranor such as the improvement of inflammation, steatosis and fibrosis. It has also a good safety profile. The whole overall efficacy of Elafibranor in the treatment of NASh is still to be proved, and we are looking forward to the results of phase III trials to determine the future of this promising drug.
Non-alcoholic Fatty Liver Disease --- Obesity --- Liver Diseases
Choose an application
viral hepatitis --- liver cirrhosis --- liver cancer --- cholestatic and biliary diseases --- metabolic liver diseases --- hepatobiliary research --- Liver --- Liver Diseases --- Foie --- Foie. --- Diseases --- Maladies.
Choose an application
Liver --- Liver Diseases. --- Gastroenterology. --- Liver. --- Malalties de l'aparell digestiu. --- Malalties del fetge. --- Gastroenterologia. --- Diseases --- Diseases. --- Malalties de l'aparell digestiu --- Malalties del fetge --- Gastroenterologia
Choose an application
Liver --- Liver. --- Malalties de l'aparell digestiu --- Malalties del fetge --- Gastroenterologia --- Liver Diseases. --- Gastroenterology. --- Diseases --- Diseases. --- Malalties de l'aparell digestiu. --- Malalties del fetge. --- Gastroenterologia.
Choose an application
Liver --- Kidney --- Hepatitis --- Hepatorenal Syndrome --- End Stage Liver Disease --- End Stage Kidney Disease --- Kidney Diseases --- Liver Diseases --- Liver Dysfunction --- Disease, Liver --- Diseases, Liver --- Dysfunction, Liver --- Dysfunctions, Liver --- Liver Disease --- Liver Dysfunctions --- Disease, Kidney --- Diseases, Kidney --- Kidney Disease --- Nephrology --- Renal Replacement Therapy --- Kidneys --- Kidney Diseases. --- Liver Diseases. --- Diseases --- Abdomen --- Urinary organs --- Diseases. --- Kidney diseases --- Nephritis --- Nephropathy --- Renal diseases --- Urology & Nephrology --- liver --- kidney --- hepatitis --- hepatorenal syndrome --- end stage liver disease --- end stage kidney disease
Listing 1 - 10 of 10 |
Sort by
|